
|Podcasts|July 21, 2022
Managed Care Cast Presents: ILD Peer Exchange—Treatment Goals in ILD, Part 2
In part 2 of this 2-part podcast, a panel of experts provide a review of the treatment landscape of systemic sclerosis interstitial lung disease (ILD) and discuss unmet needs and emerging therapies in ILD.
Advertisement
Today we are bringing you part 2 of a 2-part sponsored podcast series discussing treatment goals in insterstitial lung disease (ILD). The discussion was moderated by Ryan Haumschild, PharmD, director of Pharmacy Services at Emory Healthcare and Winship Cancer Institute.
The conversation for today’s podcast includes an in-depth review of treatment landscape of systemic sclerosis ILD as well as a discussion on unmet needs and emerging therapies in ILD.
Advertisement
Related to this article

Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.

Medigap Plan F enrollment has declined since it was closed to new beneficiaries in 2020. The percentage of individual Medigap enrollees relative to non–dually eligible traditional Medicare beneficiaries increased from 2013-2024.

Parvez Mantry, MD, shares real-world resmetirom data from AASLD 2026, including GLP-1 combination use and biopsy-sparing monitoring.

Most hospitalized COPD flare-ups aren't severe by bedside criteria, experts say, and a tiered testing bundle could guide emergency care.

SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.

Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Advertisement
Advertisement
Trending on AJMC
1
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
2
How the GOLD 2026 Guidelines Updated COPD Diagnosis and Treatment
3
CF, Bronchiectasis Antimicrobial Resistance Varies Widely by Region
4
2027 GOLD COPD Report Updates: Àlvar Agustí, MD, PhD
5

